See more : Fulum Group Holdings Limited (1443.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Cumberland Pharmaceuticals Inc. (CPIX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cumberland Pharmaceuticals Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Residential Secure Income plc (RESI.L) Income Statement Analysis – Financial Results
- Zhejiang NetSun Co., Ltd. (002095.SZ) Income Statement Analysis – Financial Results
- Novacyt S.A. (NVYTF) Income Statement Analysis – Financial Results
- BIP Bermuda Holdings I Limited (BIPI) Income Statement Analysis – Financial Results
- Lapine Co., Ltd. (8143.T) Income Statement Analysis – Financial Results
Cumberland Pharmaceuticals Inc. (CPIX)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.cumberlandpharma.com
About Cumberland Pharmaceuticals Inc.
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, rheumatology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It also develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases; and a product candidate that is in Phase II clinical trial for cholesterol reducing agent to use in the hospital setting. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 39.55M | 42.01M | 35.99M | 37.44M | 34.39M | 40.74M | 41.15M | 33.03M | 33.52M | 36.90M | 32.03M | 48.85M | 51.14M | 45.88M | 43.54M | 35.08M | 28.06M | 17.82M | 10.69M |
| Cost of Revenue | 6.07M | 9.12M | 8.81M | 8.65M | 7.42M | 7.38M | 7.37M | 5.96M | 4.97M | 5.05M | 5.44M | 5.05M | 5.36M | 3.59M | 4.14M | 3.05M | 2.67M | 2.40M | 533.26K |
| Gross Profit | 33.49M | 32.89M | 27.17M | 28.79M | 26.97M | 33.36M | 33.78M | 27.07M | 28.55M | 31.85M | 26.59M | 43.81M | 45.78M | 42.29M | 39.40M | 32.03M | 25.39M | 15.42M | 10.16M |
| Gross Profit Ratio | 84.66% | 78.29% | 75.51% | 76.89% | 78.42% | 81.89% | 82.09% | 81.96% | 85.18% | 86.31% | 83.02% | 89.67% | 89.51% | 92.18% | 90.50% | 91.32% | 90.49% | 86.53% | 95.01% |
| Research & Development | 5.83M | 6.69M | 5.68M | 5.77M | 6.87M | 7.32M | 3.90M | 3.19M | 3.85M | 3.39M | 5.62M | 5.10M | 5.03M | 4.33M | 4.99M | 4.43M | 3.69M | 2.23M | 1.16M |
| General & Administrative | 10.65M | 10.18M | 9.78M | 10.20M | 9.97M | 10.41M | 10.03M | 8.56M | 7.61M | 8.40M | 9.49M | 9.10M | 9.20M | 7.99M | 7.64M | 5.14M | 4.14M | 3.00M | 2.59M |
| Selling & Marketing | 18.45M | 16.66M | 15.02M | 14.77M | 15.28M | 20.26M | 21.49M | 14.55M | 13.99M | 14.90M | 14.39M | 20.33M | 20.94M | 22.67M | 20.19M | 14.39M | 10.05M | 7.35M | 5.65M |
| SG&A | 29.10M | 26.84M | 24.80M | 24.96M | 25.25M | 30.66M | 31.52M | 23.12M | 21.60M | 23.30M | 23.88M | 29.43M | 30.14M | 30.66M | 27.84M | 19.53M | 14.19M | 10.35M | 8.24M |
| Other Expenses | 8.10M | 5.07M | 4.37M | 4.43M | 4.13M | 2.77M | 2.44M | 2.19M | 1.99M | 1.60M | 896.16K | 466.13K | 655.30K | 686.91K | 793.68K | 791.11K | 783.43K | 611.61K | 13.49K |
| Operating Expenses | 39.39M | 38.60M | 34.85M | 35.17M | 36.26M | 40.75M | 37.86M | 28.50M | 27.44M | 28.29M | 30.39M | 34.99M | 35.93M | 35.79M | 33.62M | 24.75M | 18.67M | 13.19M | 9.41M |
| Cost & Expenses | 45.46M | 47.72M | 43.66M | 43.82M | 43.68M | 48.13M | 45.23M | 34.46M | 32.41M | 33.34M | 35.83M | 40.03M | 41.29M | 39.37M | 37.76M | 27.79M | 21.34M | 15.59M | 9.94M |
| Interest Income | 286.85K | 98.41K | 26.08K | 75.35K | 243.36K | 564.48K | 299.33K | 204.66K | 209.18K | 251.45K | 230.29K | 304.87K | 210.73K | 200.21K | 79.36K | 241.28K | 382.92K | 208.68K | 89.24K |
| Interest Expense | 667.86K | 586.00K | 98.03K | 263.63K | 246.19K | 195.85K | 92.90K | 106.39K | 73.86K | 67.07K | 103.42K | 71.99K | 353.50K | 1.42M | 772.93K | 213.30K | 639.59K | 721.80K | 63.20K |
| Depreciation & Amortization | 5.77M | 5.33M | 4.61M | 4.75M | 4.40M | 2.98M | 2.65M | 2.40M | 2.25M | 1.99M | 1.30M | 901.65K | 1.04M | 978.40K | 816.50K | 786.60K | 762.22K | 587.74K | 53.54K |
| EBITDA | 153.32K | 332.92K | -857.83K | -1.56M | -4.64M | -8.19M | -1.13M | 1.17M | 3.57M | 5.73M | -2.27M | 10.02M | 11.00M | 7.68M | 6.67M | 8.31M | 7.87M | 3.02M | 882.39K |
| EBITDA Ratio | 0.39% | -0.66% | -2.38% | -4.16% | -13.49% | -9.43% | -2.76% | 3.54% | 10.64% | 15.72% | -7.09% | 20.52% | 21.71% | 16.74% | 15.33% | 23.69% | 28.05% | 16.92% | 8.25% |
| Operating Income | -6.21M | -5.70M | -7.68M | -6.38M | -9.29M | -7.39M | -4.08M | -1.43M | -1.11M | 3.56M | -3.80M | 8.82M | 9.85M | 6.50M | 5.78M | 7.28M | 6.73M | 2.22M | 749.92K |
| Operating Income Ratio | -15.70% | -13.58% | -21.34% | -17.04% | -27.01% | -18.14% | -9.92% | -4.34% | -3.32% | 9.64% | -11.87% | 18.05% | 19.26% | 14.17% | 13.27% | 20.76% | 23.96% | 12.48% | 7.02% |
| Total Other Income/Expenses | -74.18K | 123.74K | 2.12M | -188.28K | -2.82K | 368.64K | 206.42K | 98.27K | 135.33K | 184.37K | 126.87K | 232.88K | -142.77K | -1.22M | -693.56K | 27.98K | -256.67K | -515.93K | 20.40K |
| Income Before Tax | -6.28M | -5.58M | -5.56M | -6.57M | -9.29M | -7.02M | -3.87M | -1.33M | 1.25M | 3.74M | -3.67M | 9.05M | 9.71M | 5.28M | 5.08M | 7.31M | 6.47M | 1.71M | 770.32K |
| Income Before Tax Ratio | -15.89% | -13.29% | -15.46% | -17.55% | -27.02% | -17.24% | -9.42% | -4.04% | 3.72% | 10.14% | -11.47% | 18.53% | 18.98% | 11.51% | 11.68% | 20.84% | 23.05% | 9.59% | 7.21% |
| Income Tax Expense | 45.77K | 68.85K | 34.89K | 55.90K | -79.32K | 16.64K | 4.17M | -330.92K | 575.83K | 1.38M | -1.52M | 3.24M | 4.08M | 2.85M | 2.02M | 2.54M | 2.42M | -2.70M | -1.18M |
| Net Income | -6.28M | -5.65M | -5.60M | -6.63M | -9.21M | -6.96M | -7.98M | -944.68K | 731.35K | 2.42M | -2.10M | 5.84M | 5.66M | 2.46M | 3.09M | 4.77M | 4.04M | 4.40M | 1.95M |
| Net Income Ratio | -15.88% | -13.45% | -15.55% | -17.70% | -26.79% | -17.09% | -19.39% | -2.86% | 2.18% | 6.57% | -6.57% | 11.96% | 11.06% | 5.36% | 7.10% | 13.59% | 14.41% | 24.72% | 18.28% |
| EPS | -0.44 | -0.39 | -0.38 | -0.44 | -0.60 | -0.45 | -0.50 | -0.06 | 0.04 | 0.14 | -0.11 | 0.30 | 0.28 | 0.12 | 0.22 | 0.47 | 0.40 | 0.45 | 0.21 |
| EPS Diluted | -0.44 | -0.39 | -0.38 | -0.44 | -0.60 | -0.45 | -0.50 | -0.06 | 0.04 | 0.14 | -0.11 | 0.30 | 0.28 | 0.12 | 0.17 | 0.29 | 0.24 | 0.27 | 0.12 |
| Weighted Avg Shares Out | 14.30M | 14.56M | 14.90M | 15.16M | 15.40M | 15.57M | 15.91M | 15.74M | 16.72M | 17.62M | 18.33M | 19.56M | 20.34M | 20.33M | 14.20M | 10.14M | 10.03M | 9.80M | 9.50M |
| Weighted Avg Shares Out (Dil) | 14.30M | 14.56M | 14.90M | 15.16M | 15.40M | 15.61M | 15.91M | 16.24M | 17.09M | 17.90M | 18.33M | 19.79M | 20.57M | 21.06M | 18.23M | 16.54M | 16.58M | 16.45M | 16.09M |
Will Theravance Biopharma Finally Break Out in 2020?
Staffordshire and Cheshire's first-class opponents for 2020 are announced
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Cumberland Pharmaceuticals Inc.
Source: https://incomestatements.info
Category: Stock Reports